Superiority and clinical significance of Lunx mRNA in the diagnosis of malignant pleural effusion caused by pulmonary carcinoma by Ying Tang & Lijun Xu
Tang and Xu Journal of Experimental & Clinical Cancer Research 2013, 32:37
http://www.jeccr.com/content/32/1/37RESEARCH Open AccessSuperiority and clinical significance of Lunx mRNA
in the diagnosis of malignant pleural effusion
caused by pulmonary carcinoma
Ying Tang and Lijun Xu*Abstract
Background: Pulmonary carcinoma is the main cause of malignant pleural effusions (MPEs). However, there is no
satisfactory marker for diagnosing MPEs caused by pulmonary carcinoma. The purpose of this study is to assess the
clinical significance of Lunx mRNA detection in diagnosing MPEs caused by pulmonary carcinoma.
Methods: A total of 209 patients with pleural effusions were recruited. The patients were diagnosed by cast-off cells,
bronchoscopy, and pleural biopsy. The levels of Lunx mRNA in the pleural effusions were determined by real-time
PCR. The levels of PH, LDH, glucose, albumin, and CEA were also determined. Patients who accepted chemotherapy
underwent Lunx mRNA detection before and after the first chemotherapy session. The patients were divided into
four groups according the effect of chemotherapy: complete remission (CR), partial remission (PR), no change (NC),
and progressive disease (PD). The patients were also divided into two groups according the change in direction of
Lunx mRNA expression after chemotherapy: increased group and decreased group. The patients were followed up
to determine survival.
Results: Lunx mRNA was positive in 89 of 106 patients with pleural effusions caused by pulmonary carcinoma. The
specificity and sensitivity were 95.9% and 84.9%. The area under the ROC curve was 0.922. Lunx mRNA detection was
better than detection using cast-off cells and CEA. All of the Lunx-positive patients with MPEs were diagnosed with
pulmonary carcinoma, and all extrapulmonary carcinoma patients were Lunx-negative. The positive predictive value
of Lunx mRNA for the source of tumor cells was 100%. Lunx mRNA expression decreased after the first session of
chemotherapy in the CR and PR groups, increased in the PD group, there was no change in the NC group. Further
analysis indicated the change in direction of Lunx mRNA expression was associated with the overall survival of
patients. The patients in the increased group had longer overall survival times than those in the decreased group.
Conclusion: Lunx mRNA is a specific tumor gene that is highly expressed in MPEs caused by pulmonary carcinoma.
The changes in Lunx mRNA levels after chemotherapy can predict the prognosis of patients with MPEs caused by
pulmonary carcinoma.
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Pleural effusion is a common disease that is caused by
pulmonary carcinomas and other malignant tumors,
such as breast cancer and ovarian cancer, and even some
nonmalignant diseases including tuberculosis and pneu-
monia [1,2]. Malignant pleural effusion (MPE) is usually
associated with cancer-related mortality and morbidity.* Correspondence: lijunxu001@sina.com
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reproduction in any medium, provided the orThus, it is important to diagnose MPEs and to treat and
evaluate prognosis.
Cytology detection is the conventional method used to
distinguish tumor cells in pleural effusions, as described
in the International Union Against Cancer/American
Joint Committee on Cancer’s tumor-node metastasis
(TNM) classification system [3]. However, cytology detec-
tion is imperfect in diagnosing MPEs. Moreover, when
pleural effusion cytology cannot establish a patient’s diag-
nosis, additional invasive procedures must be performed toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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diagnostic rate [2]. However, there are high risks associated
with these procedures, and many hospitals do not have
these technologies, which limits their clinical application.
Therefore, the diagnosis of MPE presents challenges to cli-
nicians, and it is urgent to search for an effective diagnostic
biomarker for this disease.
Lung cancer markers, including carcinoembryonic
antigen (CEA), neuron-specific enolase (NSE), squamous
cell carcinoma (SCC) antigen, and cytokeratin 19 (CK19),
have been generally utilized to identify malignant and
nonmalignant pleural effusions [4-7]. However, the diag-
nostic utility of these markers is unsatisfactory. Lung-
specific X protein (Lunx), which was isolated by Yoshiyuki
and colleagues through differential-display mRNA analysis,
is a 206 bp cDNA fragment specifically amplified in the
lung [8]. The Lunx gene consists of 1,015 nucleotides,
including an open reading frame of 768 nucleotides that
encodes 256 amino acids [8]. Lunx has served as a use-
ful molecular marker for the detection of pulmonary
carcinoma in bronchial brushing specimens and for the
detection of peripheral blood and lymph node metasta-
ses [9-12]. Cheng et al. [13] reported that Lunx mRNA
was the most specific biomarker with the highest sensi-
tivity when compared with CK19, CEA, vascular endo-
thelial growth factor-C (VEGF-C), and heterogeneous
ribonuclear protein (hnRNP) for the differential diagnosis
of non-small cell lung cancer from pleural effusion.
However, it is still unclear whether Lunx mRNA expres-
sion in pleural effusions can predict the source of tumor
cells and the responses of patients to chemotherapy.
Reverse transcriptase polymerase chain reaction (RT-
PCR) is the most sensitive method for the detection of
micrometastatic diseases, allowing for the detection of
one cancer cell in 106 to 107 mononuclear cells [14,15],
but it is not effective in evaluating therapeutic effect and
prognosis. Quantitative real-time RT-PCR can be used
to assess gene expression levels and further evaluate the
relationship between genes and disease. Currently, very
little information is available on the relationship between
the expression of Lunx mRNA and MPE.
The main purpose of this study was to evaluate Lunx
mRNA expression in lung cancer cells using quantitative
real-time RT-PCR, and to assess the diagnostic useful-
ness of Lunx mRNA expression as a tumor marker in
pleural effusion. Furthermore, the correlation of Lunx
mRNA expression in pulmonary carcinoma patients with
pleural effusion and clinical factors was investigated.
Methods
Patients and controls
Two hundred and nine patients with pleural effusions were
recruited from the inpatient hospital of the First Hospital
of Jilin University from July 2010 to January 2013. MPEswere diagnosed in 112 patients. Of these patients, 106
cases were pathologically shown to have pulmonary
carcinoma and six patients had extrapulmonary carcinoma.
Four patients with pathologically proven pulmonary car-
cinoma of the lung did not have MPEs. The pleural effu-
sions of three of these patients were caused by heart
failure, and the other was caused by hypoproteinemia. The
other 93 patients were diagnosed with nonmalignant
pleural effusions, including 42 caused by tuberculosis, 13
caused by pneumonia, and 38 caused by heart failure or
hypoproteinemia. The clinical characteristics of the pa-
tients are shown in Table 1. Eighty-two patients accepted
chemotherapy (Table 2), and the therapeutic effect was
evaluated after two sessions of treatment. The 82 patients
received first-line chemotherapy regimens for non-small
cell lung carcinoma (NSCLC), including navelbine plus cis-
platinum or carboplatin (NP), paclitaxel plus cis-platinum
or carboplatin (TP), gemcitabine plus cis-platinum or
carboplatin (GP), or docetaxel plus cis-platinum or
carboplatin (DP), or they received a chemotherapy regimen
for small cell lung carcinoma (SCLC), namely etoposide
plus cis-platinum (EP). Lunx mRNA expression was
detected before and after the first session of chemo-
therapy. The study was approved by the Human Ethics
Committee of Jilin University, Changchun, China. Written
informed consent was obtained from each participant.
Bronchoscopy
Patients with pleural effusions who showed a lump in pul-
monary computed tomography (CT) underwent broncho-
scope detection. They received topical anesthesia with 5 ml
of 2% lidocaine inhaled for 10–15 minutes and 2 ml of 2%
lidocaine dropped in each nostril. The bronchoscope was
inserted nasally with the patients in the supine position.
During the procedure, endobronchial or transbronchial bi-
opsy specimens were collected for histopathology. Their
specimens were sent to the department of pathology for
pathology detection by a trained specialist.
Detection of cast-off cells from pleural effusions
All patients underwent thoracentesis during hospitalization,
and 300–500 ml of pleural effusion was inspired from
the indicated patients. Then the effusion was centrifuged
at 3000 rpm for 8 min to pellet cells. The supernatant of
the effusion was removed, and the pellet of pleural effu-
sion cells was resuspended. Each sample was smeared
onto 6–8 glass slides, and fixed. Following hematoxylin-
eosin staining, the cell types were observed using a
microscope. The above steps were also completed by a
trained specialist.
Pleural biopsy
Patients who did not undergo bronchoscopy or who had
positive endobronchial or transbronchial biopsy results
Table 1 Clinical characteristics of patients
Patients with pleural
effusion








carcinoma (n = 6)Malignant (n = 106) Nonmalignant (n = 4)
Age (x ± S) 63.35 ± 9.35 61.25 ± 6.29 46.23 ± 11.56 43.38 ± 13.88 64.78 ± 8.53 51.17 ± 9.13
Sex (M/F) 55/51 2/2 7/6 20/22 20/18 2/4
Cast-off (N/P) 38/68 4/0 13/0 42/0 38/0 3/3
Pleural biopsy (n) 49 4 — 8 — 3
TNM stage
I — 3 — — — 1
II — 1 — — — 1
III — — — — — —
IV 106 — — — 4
Pathological type
SCC 26 — — — — Hepatoma 2
Ade 71 — — — — ovarian cancer 1
SCLC 9 — — — — pleural endotheliomas 1
— — — breast cancer 2
Pleural effusion (x ± S)
PH 7.42 ± 0.05 7.45 ± 0.02 7.18 ± 0.04 7.36 ± 0.04 7.45 ± 0.05 7.48 ± 0.03
LDH 665.48 ± 226.18 203.25 ± 57.64 363.46 ± 64.7 384.93 ± 93.44 135.79 ± 32.38 575.5 ± 152.28
Glu 4.52 ± 0.81 4.87 ± 0.3 4.78 ± 0.53 4.7 ± 0.58 4.74 ± 0.36 4.46 ± 0.77
Alb 46.59 ± 4.84 24.11 ± 1.57 42.47 ± 5.05 47.57 ± 4.59 22.15 ± 2.28 47.93 ± 4.63
Extrapulmonary carcinoma: including breast cancer, pleural endotheliomas, and lymphadenoma; N/P negative/positive, SCC squamous cell carcinoma,
Ade adenocarcinoma, SCLC small cell lung cancer, PH power of hydrogen, LDH lactate dehydrogenase, Glu glucose, Alb albumin —: no data.
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pleural effusion underwent pleural biopsy. The puncture
site was chosen by ultrasound. After routine disinfection
and draping, 2% lidocaine was subcutaneously injected
for local anesthesia. Then the pleural biopsy needle was
inserted into the pleural cavity via a 0.5 cm epidermal
incision. When the needle was definitely established in
pleural cavity, a hooked, blunt acupuncture needle was
inserted into the chest along the needle guard, and 3–4
left, right, and subtus parietal pleura tissues were aspirated.Table 2 Clinical characteristics and therapeutic effects in
patients with MPE caused by pulmonary carcinoma
Group CR PR NC PD
Case number 12 48 10 12
Age (x ± S) 61.16 ± 8.87 63.5 ± 9.85 63.7 ± 6.36 66.92 ± 10.92
Sex (M/F) 8/4 23/25 6/4 3/9
Pathological type
SCC 3 10 8 3
Ade 8 35 1 9
SCLC 1 3 1 0
CR complete remission, PR partial remission, NC no change, PD progressive disease,
SCC squamous cell carcinoma, Ade adenocarcinoma, SCLC small cell lung cancer.The tissues were fixed with dilute formaldehyde for further
pathological examination.Clinical parameters of pleural effusion
Five milliliters of pleural effusion were inspired from
each of the patients. The power of hydrogen (PH) was
determined with a blood gas machine (ABL700, Radiom-
eter Medical A/S, Denmark). The levels of lactate de-
hydrogenase (LDH), albumin (Alb), and glucose (Glu)
were determined with a biochemistry analyzer (AU400,
Olympus, Japan). The CEA values were determined by
the chemiluminescence immunoassay method (Beckman
Coulter, Inc., Fullerton, United States) with the upper
limit of 5 ng/ml in normal adult.Lunx detection via real-time PCR
The pleural effusion sample (15 ml) was centrifuged at
3500 rpm for 10 min to pellet cells. Then the total cellular
RNA was extracted using the Trizol reagent according to
the protocol provided by the manufacturer. Lunx detection
was performed using a Lunx mRNA fluorescence PCR
diagnostic kit (China, Anhui Puyuan Biology Technology
Corporation) according to the protocol provided by the
manufacturer. Quantitative real-time PCR was performed
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Biosystems, Foster City, United States). The standard RT
reaction contained 3.5 μl reverse transcription reaction so-
lution, 5 μl RNA solution, and 1.5 μl water without RNA
enzyme in a total volume of 10 μl. The standard PCR
contained 5 μl reverse transcription reaction solution, 5 μl
RNA solution, and 1.5 μl water without RNA enzyme in a
total volume of 25 μl. The initial PCR step was at 50°C for
2 min, followed by a 5 min hold at 95°C. The PCRs were
performed using a total of 60 cycles consisting of a 15 s
melt at 95°C, followed by a 1 min annealing/extension at
56°C. Each sample was analyzed in triplicate for the target
gene and mRNA. Copy numbers less than 103 were con-
sidered negative.
Statistical analysis
SPSS 18.0 software was used to analyze the results of real-
time PCR. The K independent samples test was used to
compare the gene expression levels in pleural effusion
among different groups, to compare pulmonary carcinoma
patients in different pathologic groups, and to compare pa-
tients before and after clinical treatment. The receiver op-
erating characteristic (ROC) curve was used to compare
the specificity and sensitivity among different indexes. In
cases where the results of gene expression were negligible,
the data were treated as 0 for statistical convenience. The
Kaplan-Meier curve was used to analyze the overall sur-
vival of patients. A value of P < 0.05 (two-tailed test) was
considered significant.
Results
General gene expression in each group
In the present study, we detected the expression of
Lunx mRNA in different pleural effusion patients. Lunx
mRNA was positively detected in 89 of the 106 patients
with pleural effusion caused by pulmonary carcinoma.
Lunx mRNA expression was not detected in patients with
heart failure/hypoproteinemia or extrapulmonary carcin-
oma. However, one patient with pneumonia and three
patients with tuberculosis were positive for Lunx mRNA
expression. The Lunx mRNA expression in different
groups is shown in Table 3. The pulmonary carcin-
oma patients with pleural effusion were grouped byTable 3 Expression of each marker in patients with pleural ef
Group n Lunx
Positive Negativ
Pulmonary carcinoma 106 89 17
Pneumonia 13 1 12
Tuberculosis 42 3 39
Heart failure/hypoproteinemia 42 0 42
Extrapulmonary carcinoma 6 0 6the TNM classification, and there were three patients in
stage I, one patient in stage II, and 106 patients in stage IV.
The expression levels in different groups are shown in
Figure 1.
RT-PCR detection of Lunx mRNA was superior to the
detection of cast-off cells and CEA in diagnosing MPEs
caused by pulmonary carcinoma
The detection of cast-off cells and CEA are commonly
used methods for diagnosing MPEs. Therefore, we
compared the efficiency of Lunx mRNA, cast-off cells,
and CEA detection in diagnosing MPEs caused by
pulmonary carcinoma and nonmalignant pleural effu-
sions. Lunx mRNA was positively detected in 93 of
209 patients with pleural effusions. Of these patients,
four were diagnosed with nonmalignant pleural effu-
sions, and the others were diagnosed with MPEs caused
by pulmonary carcinoma (Table 3). CEA was positively
detected in 87 of 209 patients with pleural effusions. Of
these patients, 73 were diagnosed with MPEs caused by
pulmonary carcinoma, and nine patients were diag-
nosed with nonmalignant pleural effusions (Table 3).
Sixty-eight patients with pleural effusions caused by
pulmonary carcinoma were positive for cast-off cells in
the pleural effusions. The specificities of detecting
Lunx mRNA, cast-off cells, and CEA were 95.9%, 100%,
and 90.7%, respectively. The sensitivities of detecting
Lunx mRNA, cast-off cells, and CEA were 84.9%, 64.2%,
and 68.9%, respectively. The area under the ROC
curve for Lunx mRNA, cast-off cells, and CEA de-
tection were 0.922, 0.821, and 0.798 (Figure 2). The op-
timal threshold for Lunx mRNA detection according to
the ROC analysis was 985 copies, and it was similar to
our positive threshold.
The relationship between the levels of Lunx mRNA and
the degree of tumor cell differentiation in pulmonary
carcinoma
According to the National Comprehensive Cancer Net-
work (NCCN) Clinical Practice Guidelines in Oncology
[16], most pleural effusions associated with lung cancer
should appear in stage IV. The effusion is not related to
the tumor in only a few patients who have had multiplefusion caused by different diseases
Cast-off CEA
e Positive Negative Positive Negative
68 38 73 33
0 13 0 13
0 42 6 36
0 42 3 39
3 3 5 1
Figure 1 Lunx mRNA expression in the pleural effusion of
indicated patients. a: Levels of Lunx mRNA in patients with pleural
effusions caused by different diseases. b: Levels of Lunx mRNA in
patients with pleural effusions caused pulmonary carcinoma at
different stages. The horizontal line indicates 103 copies/ml of Lunx
mRNA. Copy numbers less than 103 copies/ml were considered
negative. When the copy number of Lunx mRNA was not
detectable, the results were shown as number undetected.
Figure 2 ROC curve of Lunx mRNA, cast-off cells, and CEA. The
specificities for detecting Lunx mRNA, cast-off cells, and CEA are
95.9%, 100%, and 90.7%, respectively. The sensitivities for detecting
Lunx mRNA, cast-off cells, and CEA are 84.9%, 64.2%, and 68.9%,
respectively. The area under the ROC curves for detecting Lunx
mRNA, cast-off cells, and CEA are 0.922, 0.821, and 0.798,
respectively. Blue: Lunx mRNA; Green: cast-off cells; Brown: CEA.
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tive for tumor cells, and when the effusion is nonbloody
and not an exudate. Pleural effusion unrelated to the
tumor should be excluded as a stage element. In this
study, the numbers of cases in stage I, II, and III were
small, so the statistical power was insufficient when
comparing the relationship between gene expression and
TNM stage. Furthermore, we examined the relationships
between the levels of Lunx mRNA and PH, LDH, glu-
cose, albumin in the pleural effusion, histopathological
category, and the degree of tumor cell differentiation,
which referred to the degree of tumor cell differentiation
close to normal cells. There was no association between
the levels of Lunx mRNA and PH, LDH, glucose, and
albumin in the pleural effusion (data not shown). Also,
no difference was found in Lunx expression in the dif-
ferent histopathological categories (data not shown). The
levels of Lunx mRNA expression were higher in poorly
differentiated than in moderately differentiated and well
differentiated tumors (P = 0.044, P < 0.001, respectively,
Figure 3). There was no statistical difference in Lunx
mRNA expression between moderately and well differen-
tiated tumors (P = 0.066, Figure 3).Lunx mRNA expression can predict the source of
tumor cells
Lunx mRNA expression is specific to the lungs, but it was
unknown whether it could predict the source of tumor
cells in MPEs caused by pulmonary carcinoma. We ana-
lyzed Lunx mRNA expression in patients with MPEs.
There were 112 patients diagnosed with MPE including
106 pulmonary carcinoma and 6 extrapulmonary car-
cinoma patients. All of the Lunx-positive patients were
diagnosed with pulmonary carcinoma, and all of the Lunx-
negative patients were diagnosed with extrapulmonaryFigure 3 Lunx mRNA expression according to tumor
differentiation. Lunx mRNA was detected by real-time RT-PCR.
Levels of Lunx mRNA in poorly, moderately, and well differentiated
groups. The horizontal line indicates 103 copies/ml of Lunx mRNA.
Copy numbers less than 103 copies/ml were considered negative.
When the copy number of Lunx mRNA was not detectable, the
results were shown as number undetected.
Figure 5 Overall survival curves of patients after chemotherapy.
Patients were divided into the increased Lunx mRNA expression group
and decreased Lunx mRNA expression group according the direction of
change in Lunx mRNA expression. One patient was lost to follow-up
and five patients were alive in the increased Lunx mRNA expression
group, and two patients were lost and one patient was alive in the
decreased Lunx mRNA expression group. Time was calculated in weeks.
The overall survival curves are shown in blue for the increased Lunx
mRNA expression group and in green for the decreased Lunx mRNA
expression group. The individual participants are represented as
triangles. The censored data are represented by the male symbol.
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was 100%.
Changes in Lunx mRNA expression were associated with
the response of patients to chemotherapy
The 82 patients who accepted chemotherapy underwent
Lunx detection before and after the first chemotherapy
session. The relationship between the change in Lunx
mRNA expression and the response to chemotherapy
was evaluated. The standard therapeutic effect was mea-
sured according to the WHO criterion [17]. Following
chemotherapy, 12 patients had complete remission (CR),
48 patients had partial remission (PR), 10 patients had
no change (NC), and 12 patients had progressive disease
(PD). The Lunx expression decreased after the first ses-
sion of chemotherapy in the CR and PR groups (P = 0.028,
P < 0.001, respectively), there was no change in the NC
group (P = 0.912), and there was an increase in the PD
group (P = 0.023) (Figure 4).
Changes in direction of Lunx mRNA expression were
associated with the overall survival of patients
Overall survival is the best index to confirm the effective-
ness of therapy. Change in Lunx mRNA expression were
associated with the responses of patients to chemotherapy.
Therefore, it was important to assess whether the change
in Lunx mRNA expression was associated with the overall
survival of patients. The patients who accepted chemother-
apy were divided into two groups according the direction
of change in Lunx mRNA expression: increased Lunx
mRNA expression group and decreased Lunx mRNA ex-
pression group (Figure 5). Two patients with negative Lunx
expression both before and after treatment were excluded
from the analysis. There were 6 censored data (1 lost andFigure 4 Lunx mRNA expression in the pleural fluid before and
after the first chemotherapy session. Pleural fluid samples from
82 patients were collected before and after treatment and divided into
the CR, PR, NC, and PD groups. Copy numbers less than 103 copies/ml
were considered negative. When the copy number of Lunx mRNA was
not detectable, the results were shown as number undetected. CR:
complete remission, n = 12; PR: partial remission, n = 48; NC: no change,
n = 10; PD: progressive disease, n = 12.5 survival) in the increased Lunx mRNA expression
group, and 3 censored data (2 lost and 1 survival) in the
decreased Lunx mRNA expression group. The median
overall survival was 53 weeks (95% confidence interval
[CI] 44.003–61.997) in the increased Lunx mRNA ex-
pression group, and it was 25 weeks (95% CI 15.807–
34.193) in the decreased Lunx mRNA expression group.
The patients in the increased Lunx mRNA expression
group had longer overall survival times than those in the
decreased Lunx mRNA expression group (P = 0.000).
Discussion
The production of MPE is a pathological process, which
results from the failure of pleural defense mechanisms
and abnormal mesothelial function, and it is defined by
the presence of tumor cells in the pleural effusion [18].
Pulmonary carcinoma is one of the main causes of MPE
[19,20]. Patients with pleural effusion caused by pulmon-
ary carcinoma often have a short median survival [21].
The etiological diagnosis of pleural effusions is important
for evaluating the prognosis of patients. However, the
current diagnostic tests for MPEs are still unsatisfactory.
Lunx mRNA is expressed in normal lung tissues and
pulmonary carcinoma tissues, but not in other normal
or tumor tissues [8], and it has served as a useful mo-
lecular marker for the detection of pulmonary carcinoma
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role of Lunx mRNA expression in the diagnosis of
pleural effusions caused by pulmonary carcinoma. In the
present study, we found that Lunx mRNA expression
was positively detected in 89 of 106 patients with pleural
effusions caused by pulmonary carcinoma, and the area
under the ROC curve for Lunx mRNA detection was
0.922. The diagnostic utility of Lunx mRNA expression
is superior to the use of cast-off cells and CEA. These
data provide firm evidence that the detection of Lunx
mRNA expression in pleural effusion via RT-PCR is a
specific and sensitive method for diagnosing MPEs
caused by pulmonary carcinoma, and our results agree
with those of Cheng et al. [13].
Hyperplastic mesothelial cells, rhagiocrine cells, and
degenerative mesothelial cells often display special mor-
phological characteristics in the pleural effusion, which
makes it difficult to identify the source of the tumor cells
[23]. In addition, tumor cells partially lose their charac-
teristics when they unrestrictedly passage in the pleural
effusion [24]. Therefore, it is important to find markers
to distinguish the source of tumor cells. Lunx mRNA is
specifically expressed in the lungs, so we hypothesized
that positive Lunx mRNA expression may serve as a tool
to identify the source of tumor cells in pleural effusions.
In the present study, all Lunx-positive patients with
MPEs were diagnosed with pulmonary carcinoma, and all
extrapulmonary carcinoma patients were Lunx-negative.
From the above results, we conclude that if the Lunx
mRNA expression in a patient with MPE is positive, then
the source of the tumor cells should be the lungs.
Lunx mRNA is an effective marker of pulmonary
carcinoma. In the present study, we analyzed the rela-
tionship between Lunx mRNA expression and clinical
parameters. We found no association between the levels
of Lunx mRNA expression and LDH levels, glucose
levels, albumin in the pleural effusion, PH, or histo-
pathological category. However, there were significantly
increased levels of Lunx mRNA expression in poorly differ-
entiated tumors compared to moderately and well differen-
tiated tumors. The degree of tumor cell differentiation is
recognized as one index to evaluate prognosis. We pre-
sume that Lunx mRNA expression levels may be associ-
ated with the prognosis of patients with MPE caused by
pulmonary carcinoma.
Once diagnosed, chemotherapy is the main method to
treat patients with MPE caused by pulmonary carcinoma
[16]. In the CR and PR groups, we found that the expres-
sion of Lunx mRNA was significantly decreased after the
first session of chemotherapy. There was no significant
difference in the NC group; however, the expression of
Lunx mRNA significantly increased in the PD group.
These data indicate that the change in Lunx mRNA ex-
pression may be associated with the patients’ response tochemotherapy and that Lunx mRNA expression is an ef-
fective index for evaluating the effect of chemotherapy.
To investigate this idea further, we divided the patients
who accepted chemotherapy into two groups according
the change in direction of Lunx mRNA expression, and
investigated the overall survival of the patients. We found
that the patients in the increased Lunx mRNA expression
group had longer overall survival times than those in the
decreased Lunx mRNA expression group. These data
indicated that the change in direction of Lunx mRNA
expression after chemotherapy can predict the progno-
sis of patients.
Conclusions
In conclusion, Lunx mRNA is a specific tumor gene
that is highly expressed in MPE caused by pulmonary
carcinoma. The detection of Lunx mRNA before and
after chemotherapy can help clinicians predict the prog-
nosis of patients. Lunx mRNA is a sensitive marker for
distinguishing MPEs caused by pulmonary carcinoma
from pleural effusions caused by other reasons. This de-
tection may lead to the early diagnosis of patients with
MPE caused by pulmonary carcinoma.
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